Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8152W HIGH $3.20
Volume
2.71 M
Value Traded
7.27 M
Short % Float
7.61%
-4.83%Week
-13.7%1 Month
-41.2%3 Month
-41.2%6 Month
-71.19%5 Year
-95.55%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
229.22 M
EPS (TTM)
-0.07
P/E Ratio
-
Ent. Value
148.05 M
Total Shares
277.19 M
Float Shares
269.58 M
Insiders
2.71%
Institutions
40.55%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
AKBA Catalyst Timeline
Dated clinical, regulatory and corporate events for Akebia Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Akebia Therapeutics, Inc.
321Total events
18Upcoming
88Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedebribafuspTrial
First patient dosed in Phase 2 basket trial of ebribafusp in rare complement-mediated kidney diseases
IgA nephropathy, lupus nephritis and C3 glomerulopathysource ↗
●Enrollment UpdatePraliciguatTrial
Enrollment continues in Phase 2 trial of praliciguat in FSGS
FSGSsource ↗
▲Trial InitiationebribafuspTrial
Initiation of Phase 2 basket trial for ebribafusp
rare complement-mediated kidney diseases (IgA nephropathy, lupus nephritis, C3 glomerulopathy)source ↗
▲Trial InitiationebribafuspTrial
Initiated Phase 2 open-label basket trial of ebribafusp
IgA nephropathy, lupus nephritis, C3 glomerulopathysource ↗
▲Product LaunchVafseoApprovedPost-Market
Vafseo commercial launch progressing with revenue growth
Anemia due to chronic kidney disease in dialysis patientssource ↗
▼Restructuring LayoffsCorporate
Incurred $1.9 million restructuring expense related to commercial organization reorganization
▲Quarterly UpdateVafseoApprovedCorporate
Vafseo Q2 2026 net product revenues of $21.3 million
Anemia due to chronic kidney disease in dialysis patientssource ↗
▼Quarterly UpdateAuryxiaApprovedCorporate
Auryxia Q2 2026 net product revenues of $25.5 million
▲Runway Guidance UpdateCorporate
Cash resources expected to fund operations for at least two years
▲Patent GrantedVafseoApprovedIP / Competition
Composition of matter patent eligible for 5-year extension under 35 U.S.C. 156
anemia due to chronic kidney disease in adults on dialysissource ↗
●Orange Book ListingVafseoApprovedIP / Competition
New patent listed in Orange Book
anemia due to chronic kidney disease in adults on dialysissource ↗
◆Oral PresentationPresentation
Akebia Therapeutics to present at 2026 Jefferies Global Healthcare Conference
▲Interim AnalysisVafseoApprovedTrial
VOICE trial interim analysis met primary endpoint with statistically significant improved safety outcomes
Anemia due to chronic kidney disease in dialysis patientssource ↗
▲Patent GrantedVafseoApprovedIP / Competition
New Orange Book-listed patent (U.S. Patent No. 12,569,474) granted
▲Primary Endpoint MetVafseoApprovedClinical Data
VOICE trial met primary endpoint of improved safety outcomes
Anemia due to chronic kidney disease in dialysis patientssource ↗
▲PublicationVadadustatApprovedPresentation
Publication of post-hoc win statistics analysis of all-cause mortality and hospitalization from INNO2VATE program in JASN
anemia due to chronic kidney disease (CKD) in adults receiving dialysissource ↗
▲PublicationVafseoApprovedPresentation
Publication of post-hoc win statistics analysis in JASN
Anemia due to chronic kidney disease in dialysis patientssource ↗
▲First Patient DosedAKB-9090Trial
First participants dosed in Phase 1 trial of AKB-9090
cardiac surgery-associated acute kidney injurysource ↗
▲Trial InitiationAKB-9090Trial
Initiated Phase 1 study of AKB-9090 in healthy volunteers
prevention of cardiac surgery-associated acute kidney injurysource ↗
◆Oral PresentationPresentation
Fireside Chat at Leerink Partners 2026 Global Healthcare Conference
▲Enrollment UpdatePraliciguatTrial
Enrollment underway for praliciguat Phase 2 trial in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
◆Oral PresentationPresentation
Fireside Chat at Guggenheim Emerging Outlook: Biotech Summit 2026
▲Poster PresentationVafseoApprovedPresentation
Poster on cost comparison analysis of hospitalizations at Annual Dialysis Conference
anemia due to chronic kidney disease in dialysissource ↗
▲First Patient DosedPraliciguatTrial
First patient dosed in Phase 2 trial of praliciguat for FSGS
Focal Segmental Glomerulosclerosis (FSGS)source ↗
◆Trial InitiationAKB-9090Trial
AKB-9090 Phase 1 trial initiation
acute kidney injury associated with cardiac surgerysource ↗
▲First Patient DosedPraliciguatTrial
First patient dosed in Phase 2 trial of praliciguat in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
▲PublicationVafseoApprovedPresentation
Publication of win statistics analysis in Journal of the American Society of Nephrology
anemia due to chronic kidney disease in dialysissource ↗
◆Oral PresentationPresentation
Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
▲Trial InitiationPraliciguatTrial
Phase 2 trial of praliciguat initiated in FSGS
focal segmental glomerulosclerosis (FSGS)source ↗
▲Timing GuidanceVafseoApprovedPresentation
Access for 275,000 total patients across customer base expected by year-end 2025
anemia due to CKD in dialysis patientssource ↗
▲Partnership / LicenseAKB-097Corporate
Akebia acquires global rights to AKB-097 from Q32 Bio
complement-mediated rare kidney diseasessource ↗
◆Oral PresentationPresentation
Akebia management to present at Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Akebia management to present at Guggenheim Healthcare Innovation Conference
▼Trial DiscontinuedVafseoApprovedTrial
VALOR clinical trial not initiated; broad label for non-dialysis not pursued
anemia due to CKD in non-dialysis patientssource ↗
◆Enrollment MilestoneVafseoApprovedTrial
VOCAL enrollment progressing
anemia due to CKD in dialysis patientssource ↗
◆Poster PresentationVadadustatApprovedPresentation
Vadadustat Outcomes In-Center Experience (VOICE) Study: Pragmatic Randomized Controlled Trial
anemia due to chronic kidney disease (CKD) in adults on dialysissource ↗
▲Oral PresentationVafseoApprovedPresentation
Presentation of post-hoc win odds analysis of all-cause mortality and hospitalization from INNO2VATE trials at ASN Kidney Week 2025
anemia due to chronic kidney disease in dialysis-dependent adultssource ↗
◆Oral PresentationVadadustatApprovedPresentation
Win-Odds Analysis of Deaths and Hospitalization from INNO2VATE trials
anemia due to chronic kidney disease (CKD) in adults on dialysissource ↗
◆Poster PresentationVadadustatApprovedPresentation
Model-Based VAFSEO Starting Dose Recommendations in Dialysis-Dependent CKD Patients
anemia due to chronic kidney disease (CKD) in adults on dialysissource ↗
▲Oral PresentationVafseoApprovedPresentation
Post-hoc data from INNO2VATE presented at ASN Kidney Week
anemia due to CKD in dialysis patientssource ↗
▲Partnership / LicenseebribafuspCorporate
Akebia acquired global rights to ebribafusp from Q32 Bio
▼Type C MeetingVafseoApprovedFDA Meeting
Akebia completed Type C meeting with FDA regarding VALOR trial design for Vafseo in NDD-CKD
anemia due to chronic kidney disease (CKD) in non-dialysis patientssource ↗
▼Trial DiscontinuedVafseoApprovedTrial
Akebia will not initiate VALOR clinical trial for Vafseo in NDD-CKD
anemia due to chronic kidney disease (CKD) in non-dialysis patientssource ↗
Past FDA Catalysts and PDUFA Decisions
How AKBA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-06 | Vafseo® (vadadustat) | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B60 / 100
Pipeline Score
$754M
Pipeline Value
$219M
Commercial Value
Undervalued
Valuation Signal
5
Drugs Scored
11.1x
rNPV / MCap
Top 7%
Micro Cap(rank 47 of 658)
Percentile Rank
Akebia Therapeutics, Inc. holds a solid B-grade pipeline (60/100), with $3.0B risk-adjusted pipeline value, led by IW-1973 in Type 2 Diabetes Mellitus With Diabetic Nephropathy (Phase 2), across $123B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $219.1M x 1.0 = $219M
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Auryxia | $152M | $171M | -10.9% |
| Vafseo | $58M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IW-1973 Small moleculeCompletedNCT03217591 | Type 2 Diabetes Mellitus With Diabetic Nephropathy | Phase 2 | COMPLETED | 156 | Aug 20, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every AKBA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vadadustat | anemia due to chronic kidney disease | Phase 3 | 2026-05-04 | vadadustat demonstrated a statistically significant improvement relative to the erythropoiesis-stimulating agent (ESA), darbepoetin alfa, on a hierarchical composite endpoint of all-cause mortality and hospitalizationRead More | Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of NephrologyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Butler John P.Director, Officer (CEO and President) | Option | 350,000 3,718,564 held | $0.63 | 08/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AKBA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BIOIMPACT CAPITAL LLC | 1.3 % (-27.8 %) | 7.89 M | 2.89 M |
AKBA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AKBA ranks across every disease it competes in
Competitive Position is a premium feature
See how AKBA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAKBA News
AKBA▲ +1.5%today
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
Akebia Therapeutics will hold one-on-one investor meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026. Key executives, including CEO John P. Butler, will discuss the company's commercial products and clinical pipeline focused on rare kidney diseases. This engagement aims to enhance investor relations and showcase Akebia's advancements.
Read more →AKBA▲ +1.5%today
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
Akebia Therapeutics announced its participation in the ASN Kidney Week 2026, where it will present late-breaking results from the VOICE trial on vadadustat and multiple posters on its rare kidney disease pipeline. The VOICE trial evaluates vadadustat's safety in hemodialysis patients, while posters will cover preclinical and clinical findings related to praliciguat and ebribafusp alfa. Attendees can visit Akebia's booth for more information.
Read more →AKBAAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics has granted stock options to a newly-hired employee as an inducement for joining the company. The options cover 8,400 shares at an exercise price of $0.92, which aligns with the stock's closing price on the grant date. This move is part of Akebia's strategy to attract talent while adhering to Nasdaq Listing Rule 5635(c)(4).
Read more →AKBAAkebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
Akebia Therapeutics has announced the dosing of the first patient in its Phase 2 basket trial for ebribafusp, targeting rare complement-mediated kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial will evaluate the drug's safety and efficacy, with initial data expected in 2027. Ebribafusp is designed to inhibit complement activation in kidney tissues without affecting the blood system.
Read more →AKBAAkebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
Akebia Therapeutics will hold one-on-one investor meetings at the Wells Fargo Healthcare Conference in Boston from September 8 to 10, 2026. CEO John P. Butler and CFO Erik Ostrowski will present the company's commercial products and discuss its clinical pipeline focused on kidney disease. This event underscores Akebia's commitment to addressing kidney health.
Read more →AKBA▼ -26%on this news
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Akebia Therapeutics reported strong financial results for Q2 2026, with Vafseo revenues reaching $21.3 million, a 34% increase from the previous quarter. The company also announced positive interim results from the VOICE trial, demonstrating improved safety for Vafseo compared to traditional therapies. Additionally, Akebia initiated a Phase 2 trial for ebribafusp, targeting rare kidney diseases, with initial data expected in 2027.
Read more →AKBAAkebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
Akebia Therapeutics has launched a Phase 2 basket trial to assess ebribafusp, a next-generation complement inhibitor, for treating rare kidney diseases such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. The trial aims to evaluate the drug's safety, efficacy, and pharmacokinetics through weekly subcutaneous dosing. Initial data is expected in 2027.
Read more →AKBAAkebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics plans to release its financial results for Q2 2026 on August 5, 2026. The company will host a conference call at 4:30 p.m. EDT to discuss these results and recent business highlights. Investors can access the call via phone or a live webcast on Akebia's website.
Read more →AKBAU.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
The interim analysis of the VOICE trial for Vafseo® revealed significant safety benefits for U.S. patients with anemia due to chronic kidney disease (CKD) on dialysis. The trial's primary investigator decided to halt the trial based on recommendations from the Independent Data Monitoring Committee and the Trial Steering Committee, highlighting the positive outcomes observed.
Read more →AKBA▼ -5.1%on this news
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio
Akebia Therapeutics has announced the granting of a new patent for Vafseo (vadadustat), enhancing its intellectual property portfolio, which now includes 14 patents. The new patent extends the expiration of a composition of matter patent, reinforcing Akebia's competitive position in the dialysis market. Vafseo is currently the only oral HIF-PH inhibitor approved for treating anemia in chronic kidney disease patients on dialysis.
Read more →AKBA▼ -8.2%on this news
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026
Akebia Therapeutics granted stock options to a newly-hired employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The options, totaling 8,400 shares, have an exercise price of $1.02 per share and will vest over four years. This move aims to enhance employee retention and align interests with the company's performance.
Read more →AKBAAkebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Akebia Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. Key executives Erik Ostrowski and Nicholas Grund will represent the company. A live webcast of the presentation will be available, along with a replay for 90 days. The conference runs from June 2-4, 2026, in New York.
Read more →AKBA▼ -20.3%on this news
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Akebia Therapeutics reported strong financial results for the first quarter of 2026, with Vafseo® net product revenues reaching $15.8 million and a notable 60% increase in patients treated since the previous quarter. The company hosted a virtual R&D Day, showcasing ongoing clinical trials and promising developments in its kidney disease pipeline. Despite the revenue growth from Vafseo, Akebia experienced a decline in total revenues and reported a net loss, driven by fewer revenues from Auryxia. The company's cash resources are projected to support its operations for at least the next two years, reinforcing its position in the kidney disease market.
Read more →AKBA▲ +7.1%on this newsshared move
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
Akebia Therapeutics announced the publication of a post-hoc analysis from its Phase 3 INNO2VATE program, demonstrating that vadadustat significantly reduces all-cause mortality and hospitalization in patients with anemia due to chronic kidney disease receiving dialysis. The findings, published in the Journal of the American Society of Nephrology, support the potential of vadadustat as a standard treatment. However, safety concerns remain, including risks of serious adverse events.
Read more →AKBAAkebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics has announced the scheduled release of its financial results for the first quarter of 2026, set for May 7, 2026. The release will precede a conference call at 8:00 a.m. EDT, where the company will discuss both its financial performance and recent business developments. Investors can access the call through a registration link, and a live webcast will also be available via the company's website. Akebia is focused on enhancing the lives of individuals affected by kidney disease.
Read more →AKBA▲ +5%on this news
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
Akebia Therapeutics has announced that the first participants have been dosed in a Phase 1 clinical trial for AKB-9090, a drug aimed at treating cardiac surgery-associated acute kidney injury. The trial will assess the drug's safety, tolerability, and pharmacokinetics. Akebia plans to report top-line data in early 2027, indicating a significant step forward in their kidney disease pipeline.
Read more →About Akebia Therapeutics, Inc.
Headquarters245 FIRST STREET, CAMBRIDGE, MA, 02142
Founded2007
BIOPHARMAWATCH ELITE PLUS
Trade the next AKBA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime